Kindstar Globalgene Technology (9960) Fundamentals 2026 — Revenue Analysis | SniperIQ
Kindstar Globalgene Technology (9960) is a CN-listed Healthcare company in Medical - Care Facilities with a market capitalization of HK
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Kindstar Globalgene Technology's market cap?
Kindstar Globalgene Technology (9960) has a market capitalization of approximately HK
What is Kindstar Globalgene Technology's P/E ratio?
Kindstar Globalgene Technology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Kindstar Globalgene Technology?
Kindstar Globalgene Technology runs a net profit margin of -6.3%, a gross margin of 44.1%, and an operating margin of -11.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Kindstar Globalgene Technology generate?
Kindstar Globalgene Technology reported revenue of ¥934M for fiscal year 2025, with net income of -¥59M and earnings per share (EPS) of -0.0592. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Kindstar Globalgene Technology pay a dividend?
Kindstar Globalgene Technology offers a trailing dividend yield of about 9.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Kindstar Globalgene Technology financially healthy?
Kindstar Globalgene Technology carries a debt-to-equity ratio of 0.16x and a current ratio of 2.81x, with a market beta of 0.61. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Kindstar Globalgene Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kindstar Globalgene Technology (9960) the key facts are: market cap HK
Track Kindstar Globalgene Technology's full fundamentals live
Get Kindstar Globalgene Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.